2,648
Views
14
CrossRef citations to date
0
Altmetric
Original Article

Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis

, , &
Pages 64-70 | Received 03 May 2017, Accepted 03 Aug 2017, Published online: 05 Sep 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

. (2018) Theme 9 Clinical trials and trial design. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:sup1, pages 264-281.
Read now

Articles from other publishers (13)

Hidetoshi Shimizu, Yukiko Nishimura, Youichi Shiide, Makoto Akimoto, Makiko Yashiro, Masaki Ueda, Manabu Hirai, Hiide Yoshino, Tomohiko Mizutani, Kazuaki Kanai, Osamu Kano, Hideki Kimura, Hisakuni Sekino & Kimiko Ito. (2023) Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis. Clinical Therapeutics.
Crossref
J. Wes Ulm, Florian Barthélémy & Stanley F. Nelson. (2023) Elucidation of bioinformatic-guided high-prospect drug repositioning candidates for DMD via Swanson linking of target-focused latent knowledge from text-mined categorical metadata. Frontiers in Cell and Developmental Biology 11.
Crossref
Benjamin Rix Brooks, Erik P. Pioro, Takeshi Sakata, Fumihiro Takahashi, Melissa Hagan & Stephen Apple. (2023) The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis. Muscle & Nerve.
Crossref
Luca Muzio, Alma Ghirelli, Federica Agosta & Gianvito Martino. 2023. Motor System Disorders, Part II: Spinal Cord, Neurodegenerative, and Cerebral Disorders and Treatment. Motor System Disorders, Part II: Spinal Cord, Neurodegenerative, and Cerebral Disorders and Treatment 523 537 .
Hidetoshi Shimizu, Yukiko Nishimura, Youichi Shiide, Makoto Akimoto, Hideaki Matsuda, Yuichiro Kato & Manabu Hirai. (2022) Food Effect Study to Assess the Impact on Edaravone Pharmacokinetic Profiles in Healthy Participants. Clinical Therapeutics 44:12, pages 1552-1565.
Crossref
Benjamin Rix Brooks, Terry Heiman-Patterson, Martina Wiedau-Pazos, Shawn Liu, Jeffrey Zhang & Stephen Apple. (2022) Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]. PLOS ONE 17:6, pages e0258614.
Crossref
Simon Witzel, André Maier, Robert Steinbach, Julian Grosskreutz, Jan C. Koch, Anastasia Sarikidi, Susanne Petri, René Günther, Joachim Wolf, Andreas Hermann, Johannes Prudlo, Isabell Cordts, Paul Lingor, Wolfgang N. Löscher, Zacharias Kohl, Tim Hagenacker, Christian Ruckes, Birgit Koch, Susanne Spittel, Kornelia Günther, Sebastian Michels, Johannes Dorst, Thomas Meyer & Albert C. Ludolph. (2022) Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. JAMA Neurology 79:2, pages 121.
Crossref
Hidetoshi Shimizu, Yukiko Nishimura, Youichi Shiide, Kaori Yoshida, Manabu Hirai, Munetomo Matsuda, Yoshinobu Nakamaru, Yuichiro Kato & Kazuoki Kondo. (2021) Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects. Clinical Pharmacology in Drug Development 10:10, pages 1188-1197.
Crossref
Hidetoshi Shimizu, Yukiko Nishimura, Yoichi Shiide, Hideaki Matsuda, Makoto Akimoto, Munetomo Matsuda, Yoshinobu Nakamaru, Yuichiro Kato & Kazuoki Kondo. (2021) Evaluation of Pharmacokinetics, Safety, and Drug‐Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults. Clinical Pharmacology in Drug Development 10:10, pages 1174-1187.
Crossref
Marisa Cappella, Pierre-François Pradat, Giorgia Querin & Maria Grazia Biferi. (2021) Beyond the Traditional Clinical Trials for Amyotrophic Lateral Sclerosis and The Future Impact of Gene Therapy. Journal of Neuromuscular Diseases 8:1, pages 25-38.
Crossref
Juan Fernando Ortiz, Sawleha Arshi Khan, Amr Salem, Zayar Lin, Zafar Iqbal & Nusrat Jahan. (2020) Post-Marketing Experience of Edaravone in Amyotrophic Lateral Sclerosis: A Clinical Perspective and Comparison With the Clinical Trials of the Drug. Cureus.
Crossref
Jeremy Shefner, Terry Heiman‐Patterson, Erik P. Pioro, Martina Wiedau‐Pazos, Shawn Liu, Jeffrey Zhang, Wendy Agnese & Stephen Apple. (2019) Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19). Muscle & Nerve 61:2, pages 218-221.
Crossref
Magdalena Kuźma-Kozakiewicz. (2018) Edaravone in the treatment of amyotrophic lateral sclerosis. Neurologia i Neurochirurgia Polska 52:2, pages 124-128.
Crossref